A new method to induce multi-drug resistance to carboplatin in a mouse model of human tongue squamous cell carcinoma

被引:9
作者
Feng, G. [1 ]
Wang, D. -Z. [2 ]
Chen, H. -Q. [3 ]
Hu, J. [2 ]
He, J. [1 ]
机构
[1] Sichuan Univ, State Key Lab Oral Dis, Chengdu 610041, Sichuan, Peoples R China
[2] Sichuan Univ, W China Stomatol Coll, Dept Oral & Maxillofacial Surg, Chengdu 610041, Sichuan, Peoples R China
[3] Sichuan Univ, W China Ctr Med Sci, Inst Biomed Engn, Chengdu 610041, Sichuan, Peoples R China
基金
中国国家自然科学基金;
关键词
Tca8113 cell line; human tongue squamous cell carcinoma; multi-drug resistance; carboplatin;
D O I
10.1016/j.ijom.2008.06.014
中图分类号
R78 [口腔科学];
学科分类号
1003 [口腔医学];
摘要
Multi-drug resistance (MDR) in human head and neck squamous cell carcinoma (HNSCC) constitutes a major obstacle to the effectiveness of chemotherapy. In previous studies, MDR was mainly induced in vitro. The authors report a novel in vivo method of inducing MDR in nude mice with xenotransplanted Tca8113 cells. Carboplatin, a chemotherapeutic agent used to treat HNSCC, was injected around the tumors for 10 weeks. A subsequent cell survival assay of dissociated tumor cells suggested that MDR had been induced successfully. Immunocytochemistry, reverse transcription polymerase chain reaction and Western blot analysis showed that the expression levels of MDR-related proteins, including topoisomerase II, MRP and glutathione transferase, were elevated in the induction group. The authors conclude that in vivo induction of MDR provides a useful method for establishing animal models of MDR.
引用
收藏
页码:1141 / 1147
页数:7
相关论文
共 22 条
[1]
Determination of the DNA-binding characteristics of ethidium bromide, proflavine, and cisplatin by flow injection analysis:: Usefulness in studies on antitumor drugs [J].
Alonso, A. ;
Almendral, M. J. ;
Curto, Y. ;
Criado, J. J. ;
Rodriguez, E. ;
Manzano, J. L. .
ANALYTICAL BIOCHEMISTRY, 2006, 355 (02) :157-164
[2]
Human osteosarcoma xenografts and their sensitivity to chemotherapy [J].
Bruheim, S ;
Bruland, OS ;
Breistol, K ;
Maelandsmo, GM ;
Fodstad, O .
PATHOLOGY & ONCOLOGY RESEARCH, 2004, 10 (03) :133-141
[3]
Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel [J].
Chang, Chih-Chuan ;
Liang, Yu-Chuan ;
Klutz, Athena ;
Hsu, Chuan-I ;
Lin, Chien-Fu ;
Mold, David E. ;
Chou, Ting-Chao ;
Lee, Yuan Chuan ;
Huang, Ru Chih C. .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 58 (05) :640-653
[4]
Cisplatin resistance in cyclic AMP-dependent protein kinase mutants [J].
Cvijic, ME ;
Yang, WL ;
Chin, KV .
PHARMACOLOGY & THERAPEUTICS, 1998, 78 (02) :115-128
[5]
Experimental therapy of human endometrial cancers with a targeted cytotoxic bombesin analog AN-215: Low induction of multidrug resistance proteins [J].
Engel, JB ;
Schally, AV ;
Halmos, G ;
Baker, B ;
Nagy, A ;
Keller, G .
EUROPEAN JOURNAL OF CANCER, 2005, 41 (12) :1824-1830
[6]
Targeted therapy with a cytotoxic somatostatin analog, AN-238, inhibits growth of human experimental endometrial carcinomas expressing multidrug resistance protein MDR-1 [J].
Engel, JB ;
Schally, AV ;
Halmos, G ;
Baker, B ;
Nagy, A ;
Keller, G .
CANCER, 2005, 104 (06) :1312-1321
[7]
Koshiyama M, 2001, ANTICANCER RES, V21, P2925
[8]
Kubota T, 1995, CLIN CANCER RES, V1, P1537
[9]
Preliminary individual adjuvant chemotherapy for primary central nervous system lymphomas based on the expression of drug-resistance genes [J].
Kunishio K. ;
Okada M. ;
Matsumoto Y. ;
Nagao S. .
Brain Tumor Pathology, 2004, 21 (2) :57-61
[10]
DRUGS 5 YEARS LATER - CISPLATIN [J].
LOEHRER, PJ ;
EINHORN, LH .
ANNALS OF INTERNAL MEDICINE, 1984, 100 (05) :704-713